Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/136280Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Salehi, B | |
| dc.creator | Fokou, P | |
| dc.creator | Sharifi-Rad, M | |
| dc.creator | Zucca, P | |
| dc.creator | Pezzani, R | |
| dc.creator | Martins, N | |
| dc.creator | Sharifi-Rad, J | |
| dc.date.accessioned | 2021-09-20T10:52:39Z | - |
| dc.date.available | 2021-09-20T10:52:39Z | - |
| dc.date.issued | 2019 | |
| dc.identifier.issn | 1424-8247 | |
| dc.identifier.uri | https://hdl.handle.net/10216/136280 | - |
| dc.description.abstract | Naringenin is a flavonoid belonging to flavanones subclass. It is widely distributed in several Citrus fruits, bergamot, tomatoes and other fruits, being also found in its glycosides form (mainly naringin). Several biological activities have been ascribed to this phytochemical, among them antioxidant, antitumor, antiviral, antibacterial, anti-inflammatory, antiadipogenic and cardioprotective effects. Nonetheless, most of the data reported have been obtained from in vitro or in vivo studies. Although some clinical studies have also been performed, the main focus is on naringenin bioavailability and cardioprotective action. In addition, these studies were done in compromised patients (i.e., hypercholesterolemic and overweight), with a dosage ranging between 600 and 800 µM/day, whereas the effect on healthy volunteers is still debatable. In fact, naringenin ability to improve endothelial function has been well-established. Indeed, the currently available data are very promising, but further research on pharmacokinetic and pharmacodynamic aspects is encouraged to improve both available production and delivery methods and to achieve feasible naringenin-based clinical formulations. | |
| dc.description.sponsorship | N.M. would like to thank the Portuguese Foundation for Science and Technology (FCT–Portugal) for the Strategic project ref. UID/BIM/04293/2013 and “NORTE2020—Programa Operacional Regional do Norte” (NORTE-01-0145-FEDER-000012). | |
| dc.language.iso | eng | |
| dc.publisher | MDPI | |
| dc.relation | info:eu-repo/grantAgreement/FCT/5876/147342/PT | |
| dc.relation.ispartof | Pharmaceuticals, vol.12(1):11 | |
| dc.rights | openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Cardiovascular diseases | |
| dc.subject | Chemopreventive | |
| dc.subject | Citrus | |
| dc.subject | Flavanones | |
| dc.subject | Flavonoids | |
| dc.subject | Nutraceutics | |
| dc.subject | Phytochemicals | |
| dc.title | The therapeutic potential of naringenin: A review of clinical trials | |
| dc.type | Artigo em Revista Científica Internacional | |
| dc.contributor.uporto | Instituto de Investigação e Inovação em Saúde | |
| dc.identifier.doi | 10.3390/ph12010011 | |
| dc.relation.publisherversion | https://www.mdpi.com/1424-8247/12/1/11 | |
| Appears in Collections: | I3S - Artigo em Revista Científica Internacional | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 10.3390-ph12010011.pdf | 677.99 kB | Adobe PDF | ![]() View/Open |
This item is licensed under a Creative Commons License
